GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Linike Medical Group LNMG · USD

N/A · US listing · 🇺🇸 United States

Compare

0.01

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$10.7m

FY2018FY2025

Net income

$3.1m

FY2018FY2025

Free cash flow

−$262,710

FY2018FY2025

Shareholders' equity

$38.0m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Revenue$10.7m$13.0m$9.0m————
Gross profit$10.5m$13.0m$8.9m————
Operating income$3.1m−$244,879$991,040−$65,980−$29,860−$88,570−$1,080
Net income$3.1m−$244,879$991,040−$65,979−$29,861−$88,566−$1,075
Diluted earnings per share0.00-0.000.00-0.00-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Total assets$57.7m$55.6m$54.7m$1,413$3,746$3,500—
Cash and short-term investments$491,821$687,914$789,411$1,413$1,143——
Total liabilities$19.7m$20.7m$19.6m$76,683$51,879$21,771—
Debt$17.4m$18.2m$17.1m$63,305$44,158$20,733—
Shareholders' equity$38.0m$34.9m$35.1m−$75,270−$48,133−$18,271—
Shares outstanding669m669m669m639m509m669m669m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Cash from operations−$15,311−$766,546−$2.3m−$19,146−$22,012−$20,824—
Capital spending−$247,399−$228,104−$58,785————
Free cash flow−$262,710−$994,650−$2.3m−$19,146−$22,012−$20,824—

Latest quarters

By quarter end

Jul 2026Apr 2026Jan 2026Oct 2025Jan 2025Oct 2024Jul 2024Apr 2024
Revenue$3.1m$2.5m$2.4m$1.4m$3.6m$3.6m$3.5m$1.4m
Gross profit$3.1m—$2.2m—$3.4m$3.6m$3.5m$1.4m
Operating income$278,659$248,474$242,936$389,478$2.4m$218,928−$480,894−$694,550
Net income$278,658$248,474$242,935$389,478$2.4m$218,928−$480,893−$694,554
Diluted earnings per share0.000.000.000.000.000.00-0.00-0.00
Cash from operations$1.0m−$1.0m———−$1.0m——
Total assets$56.2m$56.6m$57.4m$57.7m$57.7m$55.6m$56.2m$55.6m
Cash and short-term investments$109,334$41,526$477,000$491,821$217,449$687,914$1.6m$136,266
Debt$4.4m$4.8m$5.3m$5.6m$6.2m$6.3m$5.1m$4.6m
Shareholders' equity$38.8m$38.5m$38.2m$38.0m$37.3m$34.9m$34.7m$35.2m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue——67.9%
Operating income——54.4%
Net income——58.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin99.2%———
Operating margin12.0%———
Net margin12.0%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Price to earnings0.3-1.31.0-14.3-2.7-0.0-12.6
Price to sales0.10.00.1————

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-25%-68%0%846%4530%-97%461%80%150%0%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 50-to-1 reverse split · 8 Jun 2020
  • 200-to-1 reverse split · 16 May 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.